AstraZeneca and Merck & Co announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib).
The approval is as follows:
New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primar